HemaCare Co. (OTCMKTS:HEMA) – Equities research analysts at Dougherty & Co issued their Q3 2018 earnings per share estimates for HemaCare in a report issued on Wednesday, November 28th. Dougherty & Co analyst K. Bauser forecasts that the company will earn $0.20 per share for the quarter. Dougherty & Co has a “Buy” rating on the stock. Dougherty & Co also issued estimates for HemaCare’s FY2018 earnings at $0.35 EPS and FY2019 earnings at $0.32 EPS.
OTCMKTS HEMA opened at $10.50 on Monday.
HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy.
See Also: How does a reverse stock split work?
Receive News & Ratings for HemaCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HemaCare and related companies with MarketBeat.com's FREE daily email newsletter.